Free Trial

Joint Q1 2024 Earnings Report

Joint logo
$10.64 -0.33 (-3.01%)
(As of 04:00 PM ET)

Joint Earnings Headlines

Joint (NASDAQ:JYNT) May Have Issues Allocating Its Capital
Why I'm telling friends to avoid gold stocks
Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
See More Joint Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Joint? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Joint and other key companies, straight to your email.

About Joint

Joint (NASDAQ:JYNT) operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

View Joint Profile

More Earnings Resources from MarketBeat

Upcoming Earnings